A study, led by researchers at the UCLA Jonsson Comprehensive Cancer Center, found that targeting a metabolic process in people with a specific genetic mutation could help treat glioblastoma.
Intratumoral delivery of an engineered oncolytic virus, DNX-2401, targeting glioblastoma cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of patients with recurrent GBM, according to results from a multi-institutional phase I/II clinical trial co-led by researchers at MD Anderson Cancer Center and the University of Toronto.
A phase III clinical trial data published May 2 in Cell Reports Medicine found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma.
The FIGHT-207 trial, led by Jordi Rodon, associate professor of Investigational Cancer Therapeutics at MD Anderson Cancer Center, demonstrated promising early signs of clinical benefit and revealed potential mechanisms of primary and secondary resistance following treatment with the selective FGFR inhibitor pemigatinib in patients with advanced FGFR-altered solid tumors.
New research led by investigators at Massachusetts General Hospital shows that the blood pressure drug losartan can prevent immunotherapy-induced edema in patients with glioblastoma.
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, collaborating with international researchers, have developed an AI algorithm that performs advanced computational analysis to identify potential therapeutic targets for glioblastoma multiforme and other cancers.
Cooling brain tumor cells to stop them from dividing without killing healthy cells extended the survival of glioblastoma animal models dramatically in a study led by a UT Southwestern resident.
Duke Health researchers have identified a unique process within the environment of glioblastoma brain tumors that drives resistance to immune-boosting therapies and could be targeted to promote the effects of those drugs.
A new study—published this week in Science Advances—uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma.
A new class of small molecule drugs, now in phase I clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and spread of glioblastoma.
